Co-Diagnostics Begins Clinical Testing for Respiratory Multiplex PCR Test
The company aims to support FDA 510(k) clearance submission for its point-of-care platform detecting flu A/B, COVID-19, and RSV.
The company aims to support FDA 510(k) clearance submission for its point-of-care platform detecting flu A/B, COVID-19, and RSV.
The system combines enhanced sensitivity with automation to detect M-proteins at low concentrations, supporting early diagnosis of plasma cell disorders.
The system is designed to handle more than 10,000 injections without cleaning and scan over 900 SRM transitions per second for high-throughput laboratories.
Researchers identify critical flaws in Oxford Nanopore devices that could expose or alter genetic data without detection.
The molecular diagnostic system can identify complicated UTI pathogens and antibiotic resistance markers at the point-of-care in approximately 15 minutes.